title: Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain.
abstract: The objective of this international, multicenter, open-label trial was to assess the efficacy and safety of up to 12 months of therapy with transdermal therapeutic system (TTS) fentanyl in patients (n = 532) with chronic noncancer pain. The trial was completed by 301 (57%) of the patients. The main outcome measures were pain control assessment, global treatment satisfaction, patient preference for TTS fentanyl, and quality of life. The mean dose of transdermal fentanyl (TDF) increased from 48 to 90 microg/h during a period of 12 months. During treatment, on average 67% of patients within the efficacy analysis group (n = 524) reported very good, good, or moderate pain control. Global satisfaction (very good or good) was also stable at 42%. The majority (86%) of patients reported a preference for TDF over their previous treatment (P < .001, binomial test). Short Form 36 quality-of-life scores improved from baseline for bodily pain. The most frequent treatment-related adverse events were nausea (31%), constipation (19%), and somnolence (18%). With regard to opioid-specific adverse events (respiratory depression [< 1%], adrenal insufficiency [< 1%], drug abuse/dependence [1%], and opioid withdrawal syndrome [3%]), these were extremely rare and, with the exception of opioid withdrawal syndrome, none was considered definitively related to the treatment. Long-term treatment with TDF provided a stable degree of pain control in the majority of patients with moderate to severe chronic noncancer pain. It was preferred by the majority of patients compared with their previous opioid medication. Overall, long-term treatment with TDF was generally well tolerated, particularly in view of the low incidence of potentially serious side effects such as drug abuse/dependence and respiratory depression. However, at present, it is important that patients receiving TDF should still be subject to careful assessment and monitoring.
authors: Anesthetic Department, South Cleveland Hospital, Middleborough, UK. doctor@kamilligan.freeserve.co.uk
authors: K
authors: K
authors: Milligan
authors: M
authors: M
authors: Lanteri-Minet
authors: K
authors: K
authors: Borchert
authors: H
authors: H
authors: Helmers
authors: R
authors: R
authors: Donald
authors: H G
authors: HG
authors: Kress
authors: H
authors: H
authors: Adriaensen
authors: D
authors: D
authors: Moulin
authors: V
authors: V
authors: Järvimäki
authors: L
authors: L
authors: Haazen